Viewing Study NCT03102320

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:12 AM
Ignite Modification Date: 2026-01-28 @ 10:33 PM
Study NCT ID: NCT03102320
Status: COMPLETED
Last Update Posted: 2022-06-30
First Post: 2017-03-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Sponsor: Bayer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None cholangiocarcinoma View
None pancreatic cancer View
None triple-negative breast cancer View
None non-small cell lung cancer View
None thymic carcinoma View
None gastric including gastroesophageal junction cancer View